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Technical Note
Introduction
Premature chromosome condensation (PCC) occurs when 
cells begin mitosis before completing DNA replication. 
Previously, we identified mutations in the MCPH1 gene as a 
cause of PCC.1,2 MCPH1 (Microcephalin) is a multifunc-
tional protein involved in cell cycle checkpoint control, the 
DNA damage response pathway, and chromatin remodel-
ing.3,4 This identifies the gene as a candidate tumor suppres-
sor that may also play a role in resistance to chemotherapy 
drugs.
In support of this, previous work in our and other labora-
tories has demonstrated loss or reduction of MCPH1 expres-
sion in breast and ovarian tumors, correlating with increases 
in tumor stage and aggression.5–7 Furthermore, MCPH1 has 
been identified as a transcriptional regulator of the BRCA1 
and hTERT genes, further implicating it in the control of 
cell proliferation and tumorigenesis.8,9
The PCC phenotype, seen previously in ovarian, breast, 
and colon cancers, is a reliable readout of a loss of MCPH1 
function.2,10 Here we exploit this phenotype to present the 
first report of a high-throughput reverse genetics study aimed 
at identifying both modifiers of PCC and inducers of syn-
thetic lethality in MCPH1-deficient cells. The assay could 
also be used for small-molecule screening to identify poten-
tial lead compounds that either rescue the normal functions 
of MCPH1 or selectively kill cancer cells deficient in 
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Abstract
Premature chromosome condensation (PCC) is a consequence of early mitotic entry, where mitosis begins before 
completion of DNA replication. Previously we have identified mutations in MCPH1, a DNA damage response and potential 
tumor suppressor gene, as a cause of primary microcephaly and PCC. Here we describe a high-throughput assay to identify 
modifiers of PCC. Reverse transfection of control siRNA followed by a forward transfection of MCPH1 small interfering 
RNA (siRNA) was performed to induce PCC. Condensin II subunits CAPG2 and CAPH2 were validated as PCC modifiers 
and therefore positive controls. Cell nuclei were detected by DAPI staining using an Operetta imaging system. PCC and 
nuclei number were determined using Columbus analysis software. Two batches of nine plates were used to determine 
assay efficacy. Each plate contained four negative (nontargeting) and eight positive control siRNAs. Mean % PCC was 
12.35% (n = 72) for negative controls and 4.25% (n = 144) for positive controls. Overall false-positive and false-negative 
rates were 0% (n = 72) and 2.1% (n = 144), respectively. This assay is currently being used to screen a human druggable 
genome siRNA library to identify novel therapeutic targets for cancer treatment. The assay can also be used to identify 
novel compounds and genes that induce PCC.
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MCPH1. The identification of these targets and compounds, 
alongside studies of the cellular pathways they are involved 
in, could enhance drug discovery for breast and ovarian can-
cers resistant to current chemotherapies. Currently, versions 
of the PCC assay described here are also being applied to 
small-molecule and whole-genome small interfering RNA 
(siRNA) screens aimed at identifying compounds and genes 
that induce PCC in the presence of functional MCPH1, with 
the aim of increasing our understanding of the global regula-
tion of DNA condensation.
Materials and Methods
Cell culture
Human osteosarcoma (U2OS) cells from the American Type 
Culture Collection (ATCC, Manassas, VA) were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% fetal calf serum (FCS) under standard cul-
ture conditions (37 °C, 5% CO
2
). Cells were passaged at a 
split ratio of 1:8 twice a week. Cells were obtained from 
ATCC at passage 8 and were used for screening purposes 
until passage 25.
siRNA
Dharmacon siGENOME SMARTpool siRNAs (Thermo 
Fisher Scientific, Pittsburgh, PA) were supplied as lyophi-
lized pellets containing four duplexes. Pellets were recon-
stituted with 1× RNA buffer (Thermo Fisher Scientific) to a 
concentration of 2 µM using a Fluid-X XRD-384 dispenser, 
followed by 90 min of agitation on a rotary shaker. 
Reconstituted siRNA were stored in polypropylene plates 
(Matrix, Thermo Fisher Scientific, Pittsburgh, PA) at 
−80 °C. Working plates (View Plates; PerkinElmer, Waltham, 
MA) were prepared and stored at −20 °C.
siRNA Transfections
Control siRNAs (2 µM) were directly aliquoted into 96-well 
working plates (View Plates; PerkinElmer) to columns 
1 and 12. Human PLK1 siRNA (M-003290) was used as a 
positive transfection control with reduced cell number as a 
functional readout. Human INCENP (M-006823) was used 
as a positive control for effects on cell number. Human 
CAPG2 (M-018283) and CAPH2 (M-016186) were used as 
positive controls for modification of MCPH1-induced PCC. 
Four wells containing nontargeting siRNAs (D-001206) per 
plate were used as negative controls. The final concentra-
tion of control and library siRNA was 50 nM.
For reverse transfection, a Fluid-X XRD-384 dispenser (at 
300 rpm) was used to add the transfection mixture: 0.1 µL 
Lipofectamine RNAiMAX transfection reagent (Invitrogen, 
Carlsbad, CA) suspended in 17.5 µL Opti-MEM-1 (1×) 
low-serum media (Invitrogen) per well. Plates were gently 
mixed on a rotary shaker at room temperature for a minimum 
of 20 min. Then, 80 µL U2OS cells per well, at a density of 
7.5 × 104 cells/mL in DMEM/10% FCS, in a uniform suspen-
sion maintained by constant magnetic stirring, was added to 
plates using a Fluid-X XRD-384 dispenser at 300 rpm.
To minimize edge effects, cells and transfection com-
plexes were left to rest in a laminar flow hood for 1 h at room 
temperature before returning to a 37 °C 5% CO
2
 incubator.11
After a 24-h incubation, a forward transfection of 
MCPH1 siRNA with the sense strand sequence 5′-CUCU–
CUGUGUGAAGCACCAdTdT-3′ was performed to induce 
PCC.2 For each well, 0.25 µL MCPH1 siRNA (40 µM) was 
mixed with 16.25 µL Opti-MEM-1 (1×) low-serum media 
(Invitrogen). Alongside this, 0.2 µL Lipofectamine 
RNAiMAX transfection reagent (Invitrogen) was mixed 
with 3.3 µL Opti-MEM-1 (1×) low-serum media and incu-
bated at room temperature for 5 min. The siRNA solution 
was then mixed with the transfection reagent solution and 
incubated at room temperature for a minimum of 20 min. 
The siRNA/transfection reagent mix was added to the well 
using a Fluid-X XRD-384 dispenser at 300 rpm to a final 
concentration of 100 nM.
For large-scale transfections of MCPH1, CAPG2, and 
CAPH2, forward siRNA transfections were performed in 
25-cm2 flasks. Cells were seeded at 7.5 × 104 cells per mil-
liliter in 5-mL culture media and allowed to adhere over-
night. For each siRNA, a solution of 240 µL Opti-MEM-1 
was prepared with 14.6 µL RNAiMAX. In three separate 
tubes, 1170 µL Opti-MEM-1 was mixed with 17.5 µL of 
CAPG2, CAPH2 (20 µM stock), or MCPH1 (40 µM stock) 
siRNA and incubated for 5 min at room temperature. The 
siRNA and RNAiMAX preparations were combined and 
incubated at room temperature for 20 min. Cells were rinsed 
with phosphate-buffered saline (PBS) and 5.8 mL Opti-
MEM-1 added to each flask. The siRNA suspension was 
added to the cells at a final concentration of 100 nM for 
MCPH1 and 50 nM for CAPH2 and CAPG2 and incubated 
for 4 to 6 h before DMEM supplemented with 30% FCS 
was added (10% FCS final concentration).
Quantitative Real-Time PCR
RNA was extracted using the RNeasy Plus Mini Kit 
(QIAGEN, Valencia, CA) according to the manufacturer’s 
protocol 48 h following the large-scale forward transfec-
tion. Complementary DNA (cDNA) synthesis was per-
formed using Superscript III (Invitrogen). Briefly, RNA, 
random hexamers, and dNTPs were heated to 65 °C for 
5 min and cooled on ice for 2 min. A master mix of first-
strand buffer, dithiothreitol (DTT), and Superscript III was 
added and incubated at 25 °C for 5 min before heating at 
50 °C for 50 min and finally 70 °C for 15 min. Duplicate 
real-time PCR analysis was performed using the SYBR 
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Green PCR Master Mix and 7500HT machine (Applied 
Biosystems, Foster City, CA). Details of primer sequences 
for quantitative real-time PCR (qRT-PCR) are listed in 
Supplementary Table S1.
Western Blotting
After 72 h, transfected cells were lysed in RIPA buffer 
(1% NP-40, 0.1% sodium dodecyl sulfate [SDS], 50 mM 
Tris-HCl [pH 7.4], 150 mM NaCl, 0.5% sodium deoxycho-
late, 1 mM EDTA) and quantified by the Bradford assay. 
Protein samples (40 µg) were prepared with 4× LDS sample 
buffer (Invitrogen) and 50 mM DTT and electrophorosed on 
a NuPAGE Novex 4-12% Bis-Tris gel (Invitrogen) in MES 
buffer (Invitrogen). Protein was transferred onto a PVDF 
membrane, blocked for 30 min in 10% nonfat milk in TBST 
(Tris-buffered saline [TBS]/0.1% Tween-20), and incubated 
at 4 °C overnight with a rabbit anti-MCPH1 (Abcam, 
Cambridge, UK; 1:1000 ab2612) or mouse anti–β-actin 
(Sigma, St. Louis, MO; 1:5000 100M4789) antibody. 
Horseradish peroxidase (HRP)–conjugated secondary anti-
bodies (DAKO, Glostrup, Denmark; 1:500) were added for 
an hour incubation at room temperature, followed by washes 
and visualization with Supersignal Pico/Femto (Thermo 
Fisher Scientific).
Fixation and Staining
Forty-eight hours after transfection with MCPH1 siRNA, 
media were removed by plate inversion and blotting onto 
clean paper towels to remove excess liquid. Cells were 
washed three times with 80 µL PBS, using a Fluid-X XRD-
384 dispenser at 150 rpm, dispensing to the left side of the 
well to minimize disturbance of cells. All reagents subse-
quently added to cells used these settings.
Cells were fixed for 5 min in ice-cold methanol. 
Methanol was removed from a −20 °C freezer and kept on 
ice while it was passed through the dispenser tubing for 
1 min to ensure the temperature of methanol being dis-
pensed into plates was maintained. Ice-cold methanol (80 
µL) was then dispensed into each well. Plates were placed 
in a −20 °C freezer for 5 min. After fixation, each plate was 
inverted and blotted to remove the methanol and rehydrated 
with 80 µL PBS per well.
Plates were blocked with 100 µL 1% nonfat milk pow-
der/PBS (w/v) previously clarified of particulates by cen-
trifugation at 3000 g for 20 min. DNA/nuclei were stained 
with DAPI (5 µg/mL) diluted in blocking solution. Plates 
were incubated for 1 h at room temperature in the dark.
High-Throughput Imaging
Plates were imaged with a PerkinElmer Operetta high- 
content wide-field fluorescence imaging system, coupled to 
Harmony software. Plates were automatically loaded onto 
the Operetta using a PerkinElmer Plate Handler II robotic 
arm, operated through Plateworks software. Plates were 
barcoded with specific information and barcodes were read 
before loading onto the Operetta. Wells were imaged using 
a 20× objective lens, in a single focal plane across each 
plate. The bottom of each well was detected automatically 
by the Operetta focusing laser and the focal plane calculated 
relative to this value. DAPI emission (455 nm) was imaged 
for 50 ms. Fifteen fields of view (each 510 × 675 µm) were 
imaged per well, with an identical pattern of fields used in 
every well. This pattern was designed to avoid imaging 
cells in the area targeted by the dispensers.
Image Analysis
Modified Columbus (PerkinElmer) image analysis algo-
rithms were used throughout. Nuclei were detected using a 
modified “find nuclei” algorithm as blue (DAPI) fluores-
cent regions >100 µm2, with a split factor of 7.0, an indi-
vidual threshold of 0.40, and a contrast >0.10 (method B). 
Border objects were excluded to ensure only whole nuclei 
were analyzed. The phenotypic nuclear spots characteristic 
of PCC were detected using a modified “find spots” algo-
rithm, as well as fluorescent spots with a relative spot inten-
sity >0.030 and a splitting coefficient of 1.0 (method A). 
PCC was defined as a nucleus containing 14 or more spots. 
Key output parameters were number of whole nuclei and 
percentage of nuclei with PCC.
Statistical Analysis
Statistical analysis was performed on a plate-by-plate basis 
using the z score calculation with a k value of 2, using 
CAPG2 and CAPH2 as the positive reference.12 The strictly 
standardized mean difference (SSMD) was chosen as the 
quality control metric to evaluate the variability of and the 
difference between the control siRNA populations.
Small-Scale siRNA Screen
To test the assay performance, an initial screen was per-
formed in duplicate on a batch of nine plates comprising the 
Dharmacon siGENOME SMARTpool Human Protein 
Kinase siRNA Library (G-003505).
Results and Discussion
Imaging Optimization
To identify modifiers of PCC, the PCC phenotype needed to 
be reliably and accurately induced and identified in a suffi-
cient number of cells to generate a statistically powerful 
assay. Initial experiments aimed to determine whether the 
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Operetta high-throughput screening (HTS) microscope 
and Harmony/Columbus software could achieve this. 
Previously, nuclei displaying PCC were imaged with a con-
focal microscope using a 63× objective lens, and the pro-
portion of cells with PCC was manually assessed. Although 
this gave accurate resolution of chromosome condensation 
and a reproducible PCC phenotype, the method was low 
throughput and logistically unsuitable for application to a 
high-throughput screen. Therefore, our initial aim was to 
adapt these existing methods to a high-throughput protocol 
and determine the reliability of siRNA knockdown under 
these conditions.
We have previously shown that low levels of MCPH1 
are linked with PCC in microcephaly patient lymphoblas-
toid cells and that siRNA targeting the MCPH1 gene sig-
nificantly increased the proportion of HeLa cells with PCC.2 
For the current assay, we chose the U2OS osteosarcoma cell 
line, which has a flat morphology with a large cytoplasmic 
area and grows as a consistent monolayer allowing discrete 
resolution of nuclei. Cells were seeded at a range of densi-
ties across a 96-well plate and incubated under standard 
conditions for 72 h before fixation with ice-cold methanol. 
Nuclei were stained with DAPI and imaged with the 
PerkinElmer Operetta system (Fig. 1A). Cells seeded at 
6000 cells/well reached 80% to 90% confluence at 72 h, and 
nuclei were identified as discrete objects (Fig. 1A). Images 
were taken at a single focal plane across the 96-well plate in 
the position that encompassed the widest part of the nucleus. 
Using a 20× objective lens, each field of view contained 
approximately 500 to 600 whole nuclei. Incomplete nuclei 
at the edge of the image were excluded from further analy-
sis (highlighted in red; Fig. 1A). Nuclei were determined as 
objects greater than 100 µm2 (highlighted in green; 
Fig. 1A), which excluded cell debris but included irregular 
bright nuclei likely to be cells undergoing mitosis or apop-
tosis (arrowhead in Fig. 1A; for more detail, see Suppl. Fig. 
S1). Occasional overlapping nuclei were seen and detected 
as one object (examples highlighted with arrows in Fig. 1A 
and Suppl. Fig. S1). However, this was observed only for 
one to five objects per field of view, which we deemed was 
an acceptable level for a high-throughput screen.
Determining Transfection Efficiency
We next determined the transfection efficiency of U2OS 
cells and investigated a number of potential targets for use 
as “transfection controls.” A transfection control provides a 
surrogate measure for transfection efficiency that does not 
rely on the assay end point (in this case % cells with PCC) 
to provide that information. Initial assessment of transfec-
tion efficiency with a fluorescently labeled siRNA 
(Dharmacon) required a separate assay to determine suc-
cess and was considered logistically impractical for moni-
toring transfection efficiency throughout the screening 
process (not shown). The Harmony/Columbus software that 
provides automated analysis of Operetta data requires inde-
pendent recognition of the nucleus (Fig. 1A). Therefore, 
any analysis protocol will automatically evaluate the num-
ber of nuclei within an image, providing a surrogate value 
for cell number. Hence, targeting a gene whose expression 
is crucial for cell growth and proliferation and using cell 
number as a marker is an ideal choice for a transfection 
control.
We had previously shown that silencing PLK1 by reverse 
transfection had a significant effect on cell number when 
used as a control in a screen to identify genes involved with 
cell proliferation.13 In the mouse IMCD3 (inner medullary 
collecting duct) cell line, a Dharmacon siGenome siRNA 
duplex pool targeting Plk1 significantly inhibited cell pro-
liferation compared with a nontargeting control (p < 0.0001, 
Student t test; z score <–6).13 When PLK1 was silenced in 
U2OS cells by reverse transfection, a similar effect was 
observed that functionally confirmed a successful knock-
down (Fig. 1A,B). A nontargeting siRNA control had no 
significant effect on cell number (Fig. 1B). We also investi-
gated knockdown of INCENP and KIF11 and demonstrated 
that targeting these genes and PLK1 inhibited cell prolifera-
tion such that there were >90% fewer cells compared with 
nontargeting siRNA (Fig. 1B). This indicated a high trans-
fection efficiency with these conditions. To confirm knock-
down and high transfection efficiency, we transfected U2OS 
cells with an siRNA targeting cyclophilin B, the positive 
control recommended by Dharmacon for more than 20 dif-
ferent cell lines (www.thermoscientificbio.com/resource-
library). Following transfection alongside nontargeting 
siRNA, we extracted RNA and performed qRT-PCR, dem-
onstrating 94% knockdown of cyclophilin B (Fig. 1C). This 
provided quantitative evidence that U2OS cells can be 
transfected at high levels of efficiency and supported the 
functional observations from the silencing of PLK1, 
INCENP, and KIF11 (Fig. 1B).
Identification of PCC
Crucial to the development of a PCC modifier assay is the 
consistent and reproducible generation of PCC in the U2OS 
cell line. We have previously shown that knockdown of 
MCPH1 induces PCC in HeLa cells.2 We repeated the same 
experiment for U2OS cells, using a forward transfection. 
PCC was identified using the Columbus image analysis soft-
ware to detect the number of spots present in the DAPI-
stained nuclei (Fig. 2A; PCC cells highlighted in green). This 
assay was repeated on five further passages over a number of 
weeks investigating different batches of each reagent. PCC 
was consistently <1% when cells were transfected with non-
targeting siRNA, whereas MCPH1 siRNA induced PCC in 
15% to 20% of the cell population. Mean values at each pas-
sage are shown in Figure 2B (p < 0.001, Student t test; z <–3; 
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n = 5). There was no correlation of passage number with 
baseline or induced levels of PCC, and using different batches 
of reagent had no significant effect. Next we confirmed the 
efficiency of the MCPH1 siRNA knockdown at both the 
RNA level by qRT-PCR (Fig. 2C) and the protein level by 
Western blotting (Fig. 2D).
MCPH1 also has a role in cell proliferation and apopto-
sis. Consequently, alongside assessment of PCC, we deter-
mined the effect of MCPH1 silencing on cell number. As 
previously described, nuclei number was used as a surro-
gate for cell number and assessed using an automated anal-
ysis protocol. MCPH1 siRNA reduced cell numbers by 59% 
(Fig. 2E; p < 0.001, Student t test; z <–3; n = 12), whereby 
the number of cells within 10 fields of view fell from 
approximately 6000 to 2000. To ensure that the end cell 
number was large enough to achieve statistical significance 
for the PCC modifier assay, we increased the number of 
fields of view to 15 to improve the signal-to-noise ratio.
Figure 1. Nuclei detection using Columbus and assay control validation. (A) DAPI-stained U2OS cell nuclei (blue) were imaged using 
the Operetta high-throughput screening microscope. Border objects (red) were distinguished from whole cells (green) using Harmony/
Columbus software. A significant reduction in nuclei number was seen following treatment with PLK1 small interfering RNA (siRNA) 
compared with nontargeting siRNA. Arrows indicate overlapping nuclei. Arrowhead shows a mitotic/apoptotic cell. (B) Graph showing 
transfection with INCENP, KIF11, and PLK1 siRNA caused a significant (p < 0.01)*** decrease in cell number compared with nontargeting 
siRNA, providing a quantitative and visual assessment of transfection efficiency. (C) Graph showing transfection with cyclophilin B siRNA 
caused a 94% reduction in gene expression compared with nontargeting siRNA, providing a quantitative assessment of transfection efficiency.
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Assessment of Screening Controls
To identify modifiers of PCC, our approach was to perform a 
unique double knockdown. Initially, a reverse transfection of 
positive and negative controls was performed followed by a 
forward transfection with MCPH1 siRNA to induce PCC. 
CAPG2 and CAPH2 regulatory subunits of the condensin II 
complex are involved in early prophase chromosome 
Figure 2. Premature chromosome condensation (PCC) detection and positive control validation. (A) Representative images 
from Columbus software of a U2OS input raw image. A modified “find spots” algorithm was used to detect the number of spots, 
highlighted by colored outlines, per DAPI-stained U2OS nucleus (blue). Cells with >14 spots were defined as PCC cells (green) within 
the normal cell population (red). (B) Graph showing U2OS cell passage number had no significant effect on MCPH1 small interfering 
RNA (siRNA)–induced % PCC in U2OS cells (p < 0.001). (C) Graph showing MCPH1 siRNA caused an 81% decrease in MCPH1 
gene expression compared with the nontargeting control after a 48-h transfection. (D) Western blot image confirming a reduction 
in MCPH1 protein expression in MCPH1 siRNA-treated U2OS cells after a 72-h transfection. (E) Graph showing MCPH1 siRNA 
caused a 59% (p < 0.001) decrease in cell number compared with untreated/nontargeting controls. The double-knockdown procedure 
(nontargeting/MCPH1) had no additional effect on cell number. (F) Graph to show CAPG2 and CAPH2 siRNA caused a 94% and 92% 
decrease in gene expression, respectively, in U2OS cells 48 h after transfection.
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condensation. Previously, the PCC phenotype has been 
reduced by siRNA knockdown of both subunits in micro-
cephaly patient lymphoblastoid cells and MCPH1-depleted 
HeLa cells, indicating that CAPG2 and CAPH2 are modifiers 
of the PCC phenotype.14 Therefore, we validated these genes 
as positive controls, inhibiting the induction of PCC caused 
by MCPH1 silencing. In our study, CAPG2 and CAPH2 
siRNA knockdown reduced PCC to 3.5% and 5%, respec-
tively, compared with MCPH1 siRNA transfection alone at 
12.4%. The efficiency of CAPG2 and CAPH2 siRNA knock-
down at the RNA level was confirmed by qRT-PCR (Fig. 
2F). Dharmacon-scrambled nontargeting siRNAs were 
included as negative controls. The negative controls had no 
significant effect on levels of PCC (Fig. 2B).
Next we investigated the efficacy of the double-knock-
down procedure. We anticipated that the double transfec-
tion would have a significant effect on proliferation given 
our findings of the significant loss in cell numbers caused 
by MCPH1 siRNA. Thus, we performed a reverse transfec-
tion with nontargeting siRNA (negative control) followed 
24 h later by MCPH1 knockdown. The reverse transfection 
had no significant additional effect on cell number com-
pared with MCPH1 transfection alone (Fig. 2E).
Validation of Screen
An initial screen of nine plates was performed in duplicate, 
comprising the Dharmacon siGenome protein kinase subli-
brary to determine assay efficacy. Each plate contained eight 
positive control siRNA (four CAPG2 and four CAPH2) and 
four negative (nontargeting) controls. The mean (SD) % PCC 
for positive controls was 4.0% (1.3%) for the first batch and 
4.3% (1.4%) for the second batch (total n = 72 wells) (Fig. 3). 
The mean (SD) % PCC for negative controls was 12.6% 
(2.7%) for the first batch and 12.1% (2.5%) for the second 
batch (total n = 36) (Fig. 3A). Nuclei counts for the positive 
controls (mean cell number 3133.7) did not differ signifi-
cantly from those of the nontargeting negative controls (mean 
cell number 3173) (p > 0.5, Student t test), demonstrating that 
CAPG2/CAPH2 transfections did not increase cell death. The 
reduction in PCC seen with the positive controls was there-
fore indicative of effective CAPG2/H2 knockdown rather 
than as a secondary effect due to loss of cells.
Statistical analysis was performed on a platewise basis to 
exclude plate-specific effects. Due to the robustness of the 
CAPG2 and CAPH2 data, a z score calculation that substi-
tuted positive control values for negative control values was 
used. Therefore, a z score of <2 for both replicates identi-
fied potential hits. The % PCC for the positive controls fell 
consistently below the +2 z score threshold, equating to a % 
PCC of around 5% (Fig. 3B). The overall false-positive rate 
was 0% (n = 72), and the overall false-negative rate was 
2.1% (n = 144).
The % PCC was compared between duplicate 1 of the 
screen and duplicate 2. A statistical analysis was performed, 
and the Pearson’s correlation identified a strong positive 
correlation: r = 0.6974; p < 0.0001; n = 720 (Fig. 3C). This 
Figure 3. Comparison of assay reproducibility. (A) Plots showing 
mean % premature chromosome condensation (PCC) for batches 
1 and 2 of the human protein kinase sublibrary screen. CAPG2 
small interfering (siRNA) reduced % PCC to 3.4% and 3.6%; for 
CAPH2, siRNA PCC was 4.6% and 5.4%; and for the nontargeting 
siRNA, PCC was 12.6% and 12.1%, respectively. This indicates assay 
robustness between replicates. (B) Graph showing the range of z 
scores from a single screening plate ranked from the lowest to the 
highest z score. The solid x-axis is positioned at plus 2, the cutoff 
point below which a screen hit is defined. The positive controls 
(CAPG2 and CAPH2) are highlighted in green, negative controls 
(nontargeting) are highlighted in blue, and other controls (PLK1 and 
INCENP) are highlighted in red. All positive controls are below the 
+2 cutoff that designates a hit. (C) Graph showing a comparison of 
the % PCC between duplicate 1 of the screen and duplicate 2. All 
test siRNAs are included, but control results have been removed. A 
strong positive correlation is indicated between duplicates  
(r = 0.6974; p < 0.0001; n = 720).
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demonstrated the robustness of the duplicate strategy in 
identifying modifiers of PCC.
The SSMD was calculated for each batch to exclude any 
batch-specific effects. The SSMD for the first batch of posi-
tive controls (CAPG2/CAPH2) for % PCC was 2.89 and for 
the second batch was 2.68. These values demonstrate that 
the reduction in % PCC seen with these siRNAs was 
“strong” compared with that of the nontargeting negative 
controls, reflecting the suitability of CAPG2/H2 as positive 
controls for reduced PCC.15 The SSMDs for transfection 
efficiency based on a reduction in cell number using PLK1 
and INCENP siRNA were 9.27 and 6.38 for the first batch 
and 12.12 and 7.41 for the second batch, respectively. PLK1 
and INCENP are therefore appropriate positive controls for 
effects on cell number.
To ensure a reduction in % PCC was due to the modifica-
tion of MCPH1 function rather than a secondary effect due 
to cell death as a result of siRNA toxicity, the cell number 
output from a complementary siRNA screen in U2OS cells 
without MCPH1 siRNA knockdown was used for compari-
son. Any hits that caused cell death in the complementary 
screen producing a z score of <–2 were eliminated from fur-
ther analysis. This method allows the exclusion of false-
positive hits and will be applied during the discovery phase 
of all subsequent screens. Synthetic lethality was also iden-
tified applying this approach, whereby single knockdown 
had no effect on cell number but, in combination with 
MCPH1, caused significant cell death.
We have identified eight potential modifiers of MCPH1 
function in the human protein kinase sublibrary, with one 
inducing synthetic lethality. Four individual Dharmacon 
ON-TARGETplus siRNAs that boast a superior silencing 
mechanism compared with the SMARTpools used in the 
siRNA screen will be transfected into U2OS cells and three 
ovarian cancer cell lines to minimize any off-target effects. 
Modification of MCPH1 function by the specific siRNA 
under investigation will be confirmed by the PCC readout.
In conclusion, we have developed a novel high-throughput 
protocol to detect modifiers of PCC. This assay enables the 
identification of genes whose knockdown affects PCC rate. 
Similarly, this protocol could also easily be adapted for 
large-scale small-molecule screens to identify compounds 
that reduce PCC in MCPH1-deficient cells or cause PCC in 
normal cells. This assay will facilitate the future elucidation 
of the function of MCPH1 and chromosome condensation.
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